Chief Executive Officer
Torbjörn Bjerke was appointed Chief Executive Officer in 2011. Mr Bjerke has over 20 years of experience in the pharmaceutical industry, including as President and CEO of Orexo AB, a position he held from 2007 until January 2011, President and CEO of Biolipox AB and Director of Pharmacology at AstraZeneca.
He has also served as Executive Vice President of R&D at ALK-Abello. Other appointments Chairman of Pergamum AB and Board member of NeuroSearch AS, Axelar AB, Aprea AB, Pharmanest AB and Paris-based DBV Technologies. Holdings in Karolinska Development 41,375 shares.